EPRINT集團(01884.HK)中期溢利約100萬港元 同比減少約77.7%
格隆匯11月25日丨EPRINT集團(01884.HK)公吿,截至2022年9月30日止6個月,集團收益約為1.63億港元,較截至2021年9月30日止6個月增加約900萬港元。公司權益持有人應占期內溢利約為100萬港元,較截至2021年9月30日止6個月減少約77.7%。董事會並無宣派截至2022年9月30日止6個月中期股息。
純利整體下降主要由於(其中包括)(i)集團於截至2022年9月30日止6個月期間確認的透過損益按公允價值列賬金融資產公允價值虧損約為340萬港元;及(ii)外匯虧損約220萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.